drugset / Trial / NCT07038369
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.
Timeline
- Start
- 2025-07-29
- Primary completion
- 2028-08-31
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATV-1601 | Unknown | — | Oral |
| Subject | Fulvestrant | Small molecule | — | Intramuscular |